1. Pyoderma (bacterial skin infection - impetigo/superficial pyoderma)

• General measures: gentle removal of crusts with soap and water or saline soaks; keep the area clean and dry; cut nails and discourage scratching to limit spread; wash towels/linens separately, avoid sharing them (highly contagious, spreads by direct contact and fomites).
• Localized/limited disease: topical antibiotics are first-line - mupirocin 2% ointment, retapamulin, or fusidic acid applied 2-3 times daily for about 5 days.
• Widespread, bullous, or deep disease (or if systemic symptoms/fever present): oral antibiotics covering both S. aureus and S. pyogenes - dicloxacillin, cephalexin, or amoxicillin-clavulanate. If MRSA is suspected or confirmed, use clindamycin, doxycycline, or trimethoprim-sulfamethoxazole based on local resistance patterns and culture.
• Identify and treat predisposing factors: scabies, pediculosis, atopic dermatitis, or poor hygiene, since these allow bacterial entry and recurrence.
• Complications are usually local (regional lymphadenopathy); systemic spread is uncommon, but post-streptococcal glomerulonephritis is a recognized rare sequela with S. pyogenes strains, so persistent or recurrent cases warrant follow-up.

2. Pyoderma Gangrenosum (PG)

• First-line: systemic corticosteroids (e.g., prednisone) or cyclosporine, often combined.
• Steroid-sparing/refractory disease: biologics, particularly TNF-alpha inhibitors (infliximab, adalimumab), have strong evidence, especially when PG is associated with IBD.
• Other agents used: dapsone, mycophenolate mofetil, azathioprine, or IVIG in resistant cases.
• Local wound care is essential in parallel: non-adherent dressings, avoiding aggressive debridement (which can worsen lesions via pathergy), and managing pain.
• Treating the underlying associated disease (e.g., IBD, malignancy) is important, as it often improves the skin lesions.
• A 2025 systematic review of topical treatments for PG found topical corticosteroids and calcineurin inhibitors (tacrolimus) can be effective, particularly for milder or localized lesions (PMID: 39152834), and a 2025 systematic review/meta-analysis of systemic therapies reinforces corticosteroids, cyclosporine, and biologics as mainstays (PMID: 40740034). Local wound care alone, without addressing the underlying inflammatory process, is generally insufficient (PMID: 39557450).

Recent Clinical Guidelines for Pyoderma Gangrenosum (PG) Treatment

Formal practice guidelines

• First-line: systemic corticosteroids (oral prednisolone or pulsed IV methylprednisolone) and/or cyclosporine, often used together for rapid disease control.
• Steroid-sparing/refractory disease: biologics, especially TNF-alpha inhibitors (infliximab, adalimumab), now considered near first-line in many practice settings.
• Emphasizes treating the underlying associated disease (IBD, RA, hematologic disorders) in parallel, and avoiding aggressive surgical debridement due to pathergy risk.

Supporting recent systematic reviews/meta-analyses (evidence updates, not full guidelines)

• Topical treatment systematic review (2025) - PMID: 39152834: topical corticosteroids and calcineurin inhibitors (tacrolimus) are effective for mild/localized PG, supporting their use as adjuncts or monotherapy in limited disease.
• Systemic therapies systematic review and meta-analysis (2025) - PMID: 40740034: pools outcomes across corticosteroids, cyclosporine, and biologics, reinforcing these as the systemic backbone of therapy.
• Local wound care systematic review (2024) - PMID: 39557450: non-adherent, non-aggressive wound care and appropriate bandaging matter alongside systemic immunosuppression; debridement should be used cautiously.
• Biologic agents systematic review (2025) - PMID: 41425114: synthesizes growing evidence for TNF-alpha inhibitors, IL-1 and IL-23 pathway inhibitors, and newer agents like vilobelimab (complement C5a inhibitor, reported effective in a 2024 JAMA Dermatology case).
• IVIG meta-analysis (2025), referenced within the systemic therapy review (Gan et al., JEADV 2025): supports IV immunoglobulin as an option in refractory or treatment-intolerant cases.

Practical synthesis (consistent across these sources)

1. Confirm diagnosis clinically/by exclusion (PG has no definitive biomarker) and screen for associated systemic disease (IBD, RA, hematologic malignancy, monoclonal gammopathy).
2. Mild/localized lesions: topical corticosteroids or tacrolimus +/- topical antiseptic wound care.
3. Moderate-severe or rapidly progressive disease: systemic corticosteroids and/or cyclosporine as first-line induction.
4. Refractory, steroid-dependent, or IBD-associated PG: TNF-alpha inhibitors (infliximab/adalimumab) are increasingly favored as next step, with IVIG, IL-1/IL-23 inhibitors, or other biologics for further-refractory cases.
5. Wound care: gentle, non-adherent dressings; avoid surgical debridement/grafting unless disease is quiescent, because trauma can trigger new lesions (pathergy).
6. Treat the underlying associated disease in parallel, since this often improves cutaneous control.